Breakthrough therapy is here! China's first tumor electric field treatment on the market.

"In China, where more than 45,000 patients are diagnosed with glioblastoma each year, traditional surgery and chemotherapy have limited effect on the overall survival of patients and have long lacked innovative treatments." On June 20, Deputy Director of the Beijing Institute of Neurosurgery, founder and founder of China's glioma genome mapping database, Professor Jiang Tao of Beijing Tiantan Hospital, said at the 2020 China Anti-Cancer Association Cerebral Glioma Professional Committee GBM Summit Forum and Epshield ® listing meeting that the tumor electric field treatment Ofp Dun ® this new tumor treatment program, which is expected to prolong the life of glioblastoma patients, but also opened up new ideas for the treatment of glioblastoma in China.
the world's first tumor electric field treatment epsometry ® is available in Chinese mainland for the treatment of newly diagnosed glioblastoma (GBM) patients with timozola, as well as as as a single therapy for patients with recurrent glioblastoma. At the meeting, the country's first glioma patient care platform - "first care", designed to provide all-round care and help for patients with glioma.
tumor electro-field therapy brings new hope to patients with glioblastoma
glioblastoma is the most common and invasive adult brain tumor and the highest mortality cancer except pancreatic cancer. The recurrence rate of patients was as high as 100% and the five-year survival rate was less than 5%, and was considered one of the most difficult refractive tumors in neurosurgery treatment.
and tumor electric field therapy Epshield ® mechanism is through low-intensity, medium-frequency AC electric field, acting on the microtube protein of proliferative cancer cells, interfering with tumor cells have fistic division, inhibiting tumor growth and causing the death of cancer cells affected by the electric field.
Professor Mao Ying, Chairman-designate of the Neurosurgery Branch of the Chinese Medical Association and Executive Deputy Director of Neurosurgery at Huashan Hospital affiliated with Fudan University, said: "Unlike traditional therapies such as surgery, medicine and radiotherapy, in addition to the obvious advantages in terms of efficacy, the use of tumor electric field therapy is more convenient and non-invasive, safe and controllable, and helps patients return to daily life." Clinical data also showed that for patients with good compliance, the five-year survival rate could be increased from 5% to 29.3% for patients with good compliance. "
multi-party to help the long-term survival of patients with glioma
in addition, the launch meeting, the country's first comprehensive patient care for patients with glioma public welfare project - "first care" launch. The project was initiated by the Beijing Eispectral Cancer Patient Care Foundation in cooperation with the national authoritative hospitals and experts in the field of glioma, aiming to provide various forms of expert disease science, doctor-patient interaction and other questions and answers online, to help patients with glioma to obtain professional treatment and rehabilitation guidance, to assist patients with standardized treatment and improve the quality of life."Eppand ® was approved in May this year, and we hope to make this innovative treatment available to patients as quickly as possible, providing new treatment options for eager patients," said Dr. Du Ying, founder, chairman and chief executive officer of re-e-Pharmaceuticals,
. Reding will actively work with many parties to help more patients who may benefit from the epum ® extend their lives and usher in new hopes for survival.
know that the cancer field treatment has treated more than 15,000 glioblastoma patients worldwide. In addition, several key Phase III clinical studies on tumor electro-field therapy are being conducted to assess their efficacy for brain metastasis, non-small cell lung cancer, pancreatic cancer and ovarian cancer, and Phase II clinical studies on liver and stomach cancer are under way.
References:
. Patel MA et al. Cancers. 2014; 6 (4): 1953-1985.
. Stupp R, et al. JAMA. 2015; 314 (23): 2535-2543.
.